Design Therapeutics Inc
NASDAQ:DSGN
Design Therapeutics Inc
Net Income
Design Therapeutics Inc
Net Income Peer Comparison
Competitive Net Income Analysis
Latest Figures & CAGR of Competitors
Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Design Therapeutics Inc
NASDAQ:DSGN
|
Net Income
-$66.9m
|
CAGR 3-Years
-101%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income
-$959m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Design Therapeutics Inc's Net Income?
Net Income
-66.9m
USD
Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Net Income amounts to -66.9m USD.
What is Design Therapeutics Inc's Net Income growth rate?
Net Income CAGR 3Y
-101%
Over the last year, the Net Income growth was -6%. The average annual Net Income growth rates for Design Therapeutics Inc have been -101% over the past three years .